Delic Corp to Participate at Sequire Cannabis and Psychedelic Conference and Scottsdale Capital Event

Delic Corp to Participate at Sequire Cannabis and Psychedelic Conference and Scottsdale Capital Event

Matt Stang, Co-founder and CEO of Delic Corp, will present on the Company’s strategic outlook for the remainder of the year at the Sequire Cannabis and Psychedelic Conference on April 20, 2022 and the Scottsdale Capital Event on April 22-24, 2022.

VANCOUVERBRITISH COLUMBIA, April 19, 2022 – Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today shared details regarding Matt Stang, Co-founder and CEO of Delic, and his participation at the Sequire Cannabis and Psychedelic Conference and the Scottsdale Capital Event.

  • Sequire Cannabis and Psychedelic Conference
    April 20, 2022
    Hosted by Sequire, the virtual event will bring together over 50 leading public companies in the cannabis, CBD, and psychedelic space to discuss the future of their respective industries. Stang will not only present the Company’s performance and industry outlook but also participate in one-on-one meetings with investors. To register for this year’s conference, please visit https://cannabis-conference22.mysequire.com.
  • Scottsdale Capital Event
    April 22-24, 2022
    Located in Scottsdale, Arizona, the three-day conference includes scheduled meetings and networking events with growing companies and financiers. Stang will participate in one-on-one meetings that examine the Company’s strategic outlook for the remainder of the year. To learn more about the Scottsdale Capital Event, please visit https://cem.ca/conference/scottsdale-capital-event-2022.

About Delic Corp

Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities ‎in the United States. The securities have not been and will not be registered ‎under the United States ‎Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state ‎securities laws and may not be offered or ‎sold within the United States unless registered under the U.S. ‎Securities Act and applicable state securities laws or an ‎exemption from such registration is available.‎

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of Delic’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to: information regarding the timing or terms upon which the Transaction will be completed; potential benefits of the Transaction;  anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, Delic is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of Delic to be ‎materially different from those ‎expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Transaction not closing as planned or at all or on terms and conditions set forth in the Merger Agreement; incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, Delic has made certain ‎assumptions. These assumptions include, but are not limited to: assumptions as to the time required to negotiate a definite agreement and complete matters related to the Transaction; the ability to consummate the Transaction; ‎the ability of the parties to ‎obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of ‎other conditions to the ‎consummation of the Transaction on the proposed terms; the potential impact of the announcement or consummation of the Transaction on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion ‎of management time on the Transaction.‎

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although Delic believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and Delic does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward-looking information and ‎statements ‎attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

Investor Relations Contact
Rich Rodriguez
rich@deliccorp.com

Media Contact
Phoebe Wilson
MATTIO Communications
delic@mattio.com

Delic Corp to Participate at Sequire Cannabis and Psychedelic Conference and Scottsdale Capital Event

Delic Corp to Participate at Sequire Cannabis and Psychedelic Conference and Scottsdale Capital Event

Matt Stang, Co-founder and CEO of Delic Corp, will present on the Company’s strategic outlook for the remainder of the year at the Sequire Cannabis and Psychedelic Conference on April 20, 2022 and the Scottsdale Capital Event on April 22-24, 2022.

VANCOUVERBRITISH COLUMBIA, April 19, 2022 – Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today shared details regarding Matt Stang, Co-founder and CEO of Delic, and his participation at the Sequire Cannabis and Psychedelic Conference and the Scottsdale Capital Event.

  • Sequire Cannabis and Psychedelic Conference
    April 20, 2022
    Hosted by Sequire, the virtual event will bring together over 50 leading public companies in the cannabis, CBD, and psychedelic space to discuss the future of their respective industries. Stang will not only present the Company’s performance and industry outlook but also participate in one-on-one meetings with investors. To register for this year’s conference, please visit https://cannabis-conference22.mysequire.com.
  • Scottsdale Capital Event
    April 22-24, 2022
    Located in Scottsdale, Arizona, the three-day conference includes scheduled meetings and networking events with growing companies and financiers. Stang will participate in one-on-one meetings that examine the Company’s strategic outlook for the remainder of the year. To learn more about the Scottsdale Capital Event, please visit https://cem.ca/conference/scottsdale-capital-event-2022.

About Delic Corp

Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities ‎in the United States. The securities have not been and will not be registered ‎under the United States ‎Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state ‎securities laws and may not be offered or ‎sold within the United States unless registered under the U.S. ‎Securities Act and applicable state securities laws or an ‎exemption from such registration is available.‎

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of Delic’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to: information regarding the timing or terms upon which the Transaction will be completed; potential benefits of the Transaction;  anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, Delic is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of Delic to be ‎materially different from those ‎expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Transaction not closing as planned or at all or on terms and conditions set forth in the Merger Agreement; incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, Delic has made certain ‎assumptions. These assumptions include, but are not limited to: assumptions as to the time required to negotiate a definite agreement and complete matters related to the Transaction; the ability to consummate the Transaction; ‎the ability of the parties to ‎obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of ‎other conditions to the ‎consummation of the Transaction on the proposed terms; the potential impact of the announcement or consummation of the Transaction on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion ‎of management time on the Transaction.‎

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although Delic believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and Delic does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward-looking information and ‎statements ‎attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

Investor Relations Contact
Rich Rodriguez
rich@deliccorp.com

Media Contact
Phoebe Wilson
MATTIO Communications
delic@mattio.com

Field Trip Health Ltd. to Participate in Upcoming Investor Conferences

Field Trip Health Ltd. to Participate in Upcoming Investor Conferences

TORONTO, April 18, 2022 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s management team will participate in the following investor conferences in April 2022.

Sequire Cannabis & Psychedelic Virtual Conference:
Date: April 20 at 3:00pm ET
Registration & Webcast: Click Here

KCSA Virtual Psychedelics Conference:
Date: April 27 at 10:00am ET
Registration & Webcast: Click Here
The webcast recording will also be accessible on Field Trip’s investor relations website and be found here.

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

Institutional investors interested in scheduling a meeting with Field Trip’s management team, please contact KCSA Strategic Communications at fieldtripIR@kcsa.com.

About Field Trip Health Ltd.

Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centres for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://www.meetfieldtrip.comhttps://www.fieldtriphealth.com and https://www.fieldtriphealth.nl.

Follow us on Twitter and Instagram: @fieldtriphealth.

To receive company updates about Field Trip and to be added to the email distribution list please sign up here.

Cautionary Note Regarding Forward-Looking Information  

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding Field Trip and its business. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including those set forth in the Company’s Annual Information Form and other market conditions, economic factors, management’s ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to Field Trip, including its Annual Information Form, can be located on the SEDAR website at www.sedar.com and on the EDGAR section of the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.

Neither the Toronto Stock Exchange, nor its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

CONTACTS:

Media contacts:
Rachel Moskowitz
Autumn Communications
202-276-7881
press@fieldtriphealth.com

Investor contacts:
Kathleen Heaney / Sophia Bashford / Tim Regan
KCSA Strategic Communications
fieldtripIR@kcsa.com

SOURCE Field Trip Health Ltd.

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium

– “LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy” will present the most recent and robust data on LSD in patients with anxiety –

– This study builds on decades of research on the effects of LSD in humans –

NEW YORK, April 14, 2022 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Dr. Frederike Holze and Prof. Dr. Matthias Liechti, MindMed collaborators at University Hospital Basel (UHB), will present results from the LSD-Assist Study, a Phase 2 investigator-initiated clinical trial of LSD in the treatment of anxiety disorders, at London’s PSYCH Symposium on May 11, 2022. 

The presentation, titled “LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy”, will present preliminary topline safety and efficacy results for lysergic acid diethylamide (LSD) in 46 patients with clinically significant anxiety. The trial was conducted at two centers, at UHB and at the private psychiatry practice of Dr. Peter Gasser. MindMed supports the UHB Liechti Lab in conducting investigator-initiated trials for LSD and other novel therapies and has exclusive access and rights to the data generated by these studies.

Prof. Dr. Liechti said, “Anxiety disorders are widespread and often insufficiently managed with available medications. I look forward to sharing the preliminary findings from this important study, including patients with anxiety associated with life-threatening illness but also patients with anxiety disorder without severe somatic illness, adding to our understanding of how LSD may be used safely to treat anxiety disorders.”

“Since the 1940s, LSD has been extensively investigated for its effects in humans, showing particular benefit in mitigating symptoms of anxiety and depression,” added Robert Barrow, Chief Executive Officer and Director of MindMed. “The results from this study, if positive, would further validate our approach to develop MM-120 in the treatment of Generalized Anxiety Disorder and would support the progression of our MM-120 development program. We are proud to support Dr. Liechti and his team and to extend their findings through our commercial drug development programs.”

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. 

For Media: media@mindmed.co

For Investors: ir@mindmed.co

Biomind Labs to Participate in the PSYCH Symposium at the National Gallery in London

Biomind Labs to Participate in the PSYCH Symposium at the National Gallery in London

TORONTO–(BUSINESS WIRE)–Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce that it will be participating in the “PSYCH Symposium: London 2022 – Unlocking the potential of psychedelic Healthcare” to be held at The National Gallery on Wednesday, May 11, 2022.

Alejandro Antalich, CEO of Biomind Labs commented: “The PSYCH Symposium will be one of the most relevant events in the psychedelic industry in 2022, and this is the reason why we have decided to be part of the debates with the principal leaders of the sector and use this forum to present our future plans.

Last year Prime Minister Boris Johnson said that he will examine the latest advice on the legalization of a psychedelic drug. We must confess that with this statement, Prime Minister Johnson won our respect because as a leader of a nation, he displayed empathy towards millions of patients that suffer from any kind of mental health disorder, and this kind of attitude is what is needed from global leaders.

We support the initiative of Mr. Crispin Blunt that has had a positive impact on Primer Minister Johnson, with the hope of promoting a global analysis and review of psychedelic legalization by government authorities, regulators and the psychiatry community. While more clinical research must be done, time is becoming critical for the almost one billion people that are affected by mental disorders”, concluded Mr. Antalich.

The United Kingdom is home to world-leading psychedelic research institutions, which lays the foundation for a flourishing domestic industry, with the PSYCH Symposium championing the emerging ecosystem. The PSYCH Symposium is a unique experience that enables industry leaders to collaborate to expedite access to psychedelic healthcare across Europe. As the industry expands, research briefings, regulatory updates and topical debates can provide the intelligence and insights to navigate this burgeoning landscape, while ensuring a sustainable, patient-first approach to how the industry defines itself in the future.

About Biomind Labs Inc.

Biomind Labs is a biotech research and development company aimed at transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of the main psychedelic molecules, N, N-dimethyltryptamine, 5-MeO- DMT and mescaline for treating a wide range of therapeutic indications. Biomind Labs’ focus is to provide patients access to affordable and modern-day treatments.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always

using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward-looking statements in this document include, among others, statements relating to the Company’s ability to scientifically harness the medicinal power of psychedelic molecules to treat patients suffering from neurological and psychiatric disorders, the possibility of a global analysis and review of psychedelic legalization by government authorities, regulators and the psychiatry community, any statement regarding the future impact of the PSYCH Symposium, the business plans and growth plans of the Company, the burgeoning landscape of the psychedelic industry, and other statements that are not historical facts.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others: (a) the Company may require additional financing from time to time in order to continue its operations which may not be available when needed or on acceptable terms and conditions acceptable; (b) compliance with extensive government regulation; (c) domestic and foreign laws and regulations could adversely affect the Company’s business and results of operations; (d) the stock markets have experienced volatility that often has been unrelated to the performance of companies and these fluctuations may adversely affect the price of the Company’s securities, regardless of its operating peers; (e) adverse changes in the public perception of tryptamine- based treatments and psychedelic-based therapies; (f) the impact of COVID-19; and (g) general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding tryptamine-based treatments, psychedelic-based therapies or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psychedelic tryptamines, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not yet completed commercial clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that the Company verified such in commercial clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

The forward-looking information contained in this news release represents the expectations of the Company as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. The Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Beckley Psytech to Attend and Present at 8th Annual LSX World Congress 2022

Beckley Psytech to Attend and Present at 8th Annual LSX World Congress 2022

OXFORD, England–(BUSINESS WIRE)–Apr 13, 2022–

Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the 8 th Annual LSX World Congress, taking place in London from 10 th to 11 th May 2022, and will hold a formal presentation in front of investors.

Company presentation details

  • Tuesday, 10 th May 2022, 10.30 am ET / 3.30 pm BST
  • Please register for the event here

A link to the presentation will be available on the Company’s website from 16 th May 2022.

The presentation will introduce Beckley Psytech, its target indications, pipeline of drugs and ongoing clinical trials:

  1. 5-MeO-DMT intranasal formulation safety and tolerability – Phase 1 dose ranging study, and
  2. low-dose psilocybin Phase 1b in SUNHA 1

To request a one-on-one meeting with the Beckley Psytech management team, please contact us at gvanrenterghem@lifesciadvisors.com.

-Ends-

Beckley Psytech – www.beckleypsytech.com

Beckley Psytech is a clinical stage privately held company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a broad pipeline of psychedelic compounds in rare and more common diseases. Our vision is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients with high unmet medical need around the world, suffering from Short-lasting unilateral neuralgiform headache attacks (SUNHA), treatment resistant depression and other profoundly debilitating conditions. Beckley Psytech was founded in 2019 leveraging some of the expertise developed over more than 20 years by the Beckley Foundation, an independent non-profit and world leader in psychedelic medicine research, and is based out of Oxford, United Kingdom.

1 Short-lasting unilateral neuralgiform headache attacks

View source version on businesswire.com:https://www.businesswire.com/news/home/20220412005773/en/

CONTACT: Beckley Psytech

Cosmo Feilding Mellen

Chief Executive Officer

info@beckleypsytech.com

Communications

FTI Consulting

Ben Atwell / Mike Trace

+44 (0)20 3727 1000

beckleypsytech@fticonsulting.com

Investor Relations

LifeSci Advisors

Guillaume van Renterghem

+41 76 735 01 31

gvanrenterghem@lifesciadvisors.com

KEYWORD: UNITED KINGDOM EUROPE

INDUSTRY KEYWORD: BIOTECHNOLOGY MENTAL HEALTH HEALTH PHARMACEUTICAL CLINICAL TRIALS

SOURCE: Beckley Psytech Limited

Copyright Business Wire 2022.

PUB: 04/13/2022 02:00 AM/DISC: 04/13/2022 02:02 AM

http://www.businesswire.com/news/home/20220412005773/en

Microdosing concert for group healing

Red Light Holland Sponsors First Of Its Kind Group Microdosing Concert In The Netherlands

On Saturday, Red Light Holland (TRIP) sponsored a first-of-its-kind microdosing concert to determine best practices for group microdosing services.

Participants attended a preparation session and received a customized dose of psilocybin from a therapist.

They spent the next three hours laying on the ground listening to a live classical music concert before attending an optional integration session.

“Both music and community have healing and connective qualities and we are excited to test the potential benefits of combining microdosing psilocybin truffles in this ground-breaking setting,” says one of the event organizers

Data from the event will be used to guide microdosing regulations Oregon and Washington.

PDF of article

Beckley Psytech to Attend and Present at 8th Annual LSX World Congress 2022

Beckley Psytech to Attend and Present at 8th Annual LSX World Congress 2022

OXFORD, England–(BUSINESS WIRE)–Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the 8th Annual LSX World Congress, taking place in London from 10th to 11th May 2022, and will hold a formal presentation in front of investors.

Company presentation details

  • Tuesday, 10th May 2022, 10.30 am ET / 3.30 pm BST
  • Please register for the event here

A link to the presentation will be available on the Company’s website from 16th May 2022.

The presentation will introduce Beckley Psytech, its target indications, pipeline of drugs and ongoing clinical trials:

  1. 5-MeO-DMT intranasal formulation safety and tolerability – Phase 1 dose ranging study, and
  2. low-dose psilocybin Phase 1b in SUNHA1

To request a one-on-one meeting with the Beckley Psytech management team, please contact us at gvanrenterghem@lifesciadvisors.com.

-Ends-

Beckley Psytech – www.beckleypsytech.com

Beckley Psytech is a clinical stage privately held company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a broad pipeline of psychedelic compounds in rare and more common diseases. Our vision is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients with high unmet medical need around the world, suffering from Short-lasting unilateral neuralgiform headache attacks (SUNHA), treatment resistant depression and other profoundly debilitating conditions. Beckley Psytech was founded in 2019 leveraging some of the expertise developed over more than 20 years by the Beckley Foundation, an independent non-profit and world leader in psychedelic medicine research, and is based out of Oxford, United Kingdom.


1 Short-lasting unilateral neuralgiform headache attacks

Contacts

Beckley Psytech
Cosmo Feilding Mellen
Chief Executive Officer
info@beckleypsytech.com

Communications
FTI Consulting
Ben Atwell / Mike Trace
+44 (0)20 3727 1000
beckleypsytech@fticonsulting.com

Investor Relations
LifeSci Advisors
Guillaume van Renterghem
+41 76 735 01 31
gvanrenterghem@lifesciadvisors.com

Psyched Wellness to Participate in Upcoming Investor Conferences in April 2022

Psyched Wellness to Participate in Upcoming Investor Conferences in April 2022

Psyched Wellness Ltd. is pleased to announce that Chief Executive Officer, Jeffrey Stevens, and Chief Commercial Officer, Matthew Singh, will be presenting at the following investor conferences, in April 2022.

Benzinga Psychedelics Capital Conference:

Date: April 19 at 3:00pm ET

Registration: https://www.benzinga.com/events/psychedelics/

Webcast: https://www.benzinga.com/events/psychedelics/livestream/

RHK NobleCon18:

Date: April 20 at 3:00pm ET

Registration: https://www.nobleconference.com/eighteen#register

Webcast: https://noble.mediasite.com/Mediasite/Play/eac8086a26464b159e3ae56f49d63afe1d

Mr. Singh commented: “Both Jeff and I are extremely excited to share the progress Psyched Wellness has made, in 2022. Beyond the standard introduction and insight into the positioning of our company, we will speak to the continued development of our proprietary extract, AME-1 (yielding the first legal Amanita Muscaria products in North America), the unique go-to-market benefits this extract affords us when it comes to retail upside, and our healthy financial position to execute our rollout plan, with revenue populating as early as Summer 2022. We truly believe Psyched Wellness has offerings no other company can rival.”

To schedule a one-on-one meeting with Psyched’s management team, please contact KCSA Strategic Communications at PsychedWellness@kcsa.com.

-30-


Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

About Psyched Wellness Ltd.:

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

Cautionary Statement Regarding Forward-Looking Information and Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; the uses and potential benefits of Amanita Muscaria; the Company completing its studies and reports upon the terms and timelines as disclosed herein; and the Company’s studies and reports generating the intended information and benefits.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company’s ability to continue as a going concern; the Company’s ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company’s activities by the relevant governmental and/or regulatory authorities; the continued growth of the Company; the Company completing its studies and reports upon the terms and timelines as disclosed herein; and the Company’s studies and reports generating the intended information and benefits.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company’s operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; the risk that there is no potential benefit of Amanita Muscaria consumption; the risk the Company will be unable to develop its products; the inability of the Company to complete their studies and/or reports on the intended timelines; the inability of the Company to generate reliable or positive reports therefrom; and the risk that the Company will not benefit from the studies and/or reports.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.press